@Article{Toprak2015,
journal="Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej",
issn="1734-9338",
volume="11",
number="4",
year="2015",
title="Platelet/lymphocyte ratio was associated with impaired myocardial perfusion and both in-hospital and long-term adverse outcome in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention",
abstract=" Introduction : Platelet/lymphocyte ratio (PLR) has been shown to be an inflammatory and thrombotic biomarker for coronary heart disease, but its prognostic value in ST-segment elevation myocardial infarction (STEMI) has not been fully investigated.    Aim:   To investigate the relationship between PLR and no-reflow, along with the in-hospital and long-term outcomes in patients with STEMI.   Material and methods : In the present study, we included 304 consecutive patients suffering from STEMI who underwent primary percutaneous coronary intervention (p-PCI). Patients were stratified according to PLR tertiles based on the blood samples obtained in the emergency room upon admission. No-reflow after p-PCI was defined as a coronary thrombolysis in myocardial infarction (TIMI) flow grade ≤ 2 after vessel recanalization, or TIMI flow grade 3 together with a final myocardial blush grade (MBG) < 2.   Results : The mean follow-up period was 24 months (range: 22–26 months). The number of patients characterized with no-reflow was counted to depict increments throughout successive PLR tertiles (14% vs. 20% vs. 45%, p < 0.001). In-hospital major adverse cardiovascular events and death increased as the PLR increased (p < 0.001, p < 0.001). Long-term MACE and death also increased as the PLR increased (p < 0.001, p < 0.001). Multivariable logistic regression analysis revealed that PLR remained an independent predictor for both in-hospital (OR = 1.01, 95% CI: 1.00–1.01; p = 0.002) and major long-term (OR = 1.01, 95% CI: 1.00–1.01; p < 0.001) adverse cardiac events.   Conclusions : Platelet/lymphocyte ratio on admission is a strong and independent predictor of both the no-reflow phenomenon and long-term prognosis following p-PCI in patients with STEMI.",
author="Toprak, Cuneyt
and Tabakci, Mehmet M.
and Simsek, Zeki
and Arslantas, Ugur
and Durmus, Halil I.
and Ocal, Lutfi
and Demirel, Muhittin
and Ozturkeri, Burak
and Ozal, Ender
and Kargin, Ramazan",
pages="288--297",
doi="10.5114/pwki.2015.55599",
url="http://dx.doi.org/10.5114/pwki.2015.55599"
}